Get the Finder app 🥳

Track your credit score, free


How to buy Catalyst Pharmaceuticals shares | $3.11

Own Catalyst Pharmaceuticals shares in just a few minutes.


Fact checked

Catalyst Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.11 – a decrease of 8.26% over the previous week.

How to buy shares in Catalyst Pharmaceuticals

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Catalyst Pharmaceuticals. Find the share by name or ticker symbol: CPRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalyst Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$3.11, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Catalyst Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Catalyst Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Catalyst Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Catalyst Pharmaceuticals's share price has had significant negative movement.

Its last market close was US$3.11, which is 40.31% down on its pre-crash value of US$5.21 and 21.96% up on the lowest point reached during the March crash when the shares fell as low as US$2.55.

If you had bought US$1,000 worth of Catalyst Pharmaceuticals shares at the start of February 2020, those shares would have been worth US$743.47 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$738.72.

Catalyst Pharmaceuticals share price

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

Information last updated 2020-09-20.
Latest market closeUSD$3.11
52-week rangeUSD$2.55 - USD$6.64
50-day moving average USD$3.4829
200-day moving average USD$4.1565
Target priceUSD$7.58
PE ratio 8.6923
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.389

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)


Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

  • $0 brokerage for US stocks
  • Trades starting from $50
  • Fractional shares
  • Copy top traders
Go to site
More info

Important: Share trading carries risk of capital loss.


Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 10 per month if there’s been no login for 12 months
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
IG Share Trading
Finder Award
IG Share Trading
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the last close of $3.11

1 week (2020-09-14) -7.72%
1 month (2020-08-24) -6.89%
3 months (2020-06-20) N/A
6 months (2020-03-23) -0.64%
1 year (2019-09-20) -53.02%
2 years (2018-09-21) -1.27%
3 years (2017-09-21) 27.46%
5 years (2015-09-21) -24.70%

Is Catalyst Pharmaceuticals under- or over-valued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Catalyst Pharmaceuticals shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$42.9 million (£0.0 million).

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM US$119.8 million
Operating margin TTM 35.77%
Gross profit TTM US$87.5 million
Return on assets TTM 25.54%
Return on equity TTM 47.87%
Profit margin 34.87%
Book value 1.075
Market capitalisation US$360.8 million

TTM: trailing 12 months

Shorting Catalyst Pharmaceuticals shares

There are currently 12.1 million Catalyst Pharmaceuticals shares held short by investors – that's known as Catalyst Pharmaceuticals's "short interest". This figure is 12.9% down from 13.9 million last month.

There are a few different ways that this level of interest in shorting Catalyst Pharmaceuticals shares can be evaluated.

Catalyst Pharmaceuticals's "short interest ratio" (SIR)

Catalyst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catalyst Pharmaceuticals shares currently shorted divided by the average quantity of Catalyst Pharmaceuticals shares traded daily (recently around 2.7 million). Catalyst Pharmaceuticals's SIR currently stands at 4.56. In other words for every 100,000 Catalyst Pharmaceuticals shares traded daily on the market, roughly 4560 shares are currently held short.

However Catalyst Pharmaceuticals's short interest can also be evaluated against the total number of Catalyst Pharmaceuticals shares, or, against the total number of tradable Catalyst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Catalyst Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1307% of the tradable shares (for every 100,000 tradable Catalyst Pharmaceuticals shares, roughly 131 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Pharmaceuticals.

Find out more about how you can short Catalyst Pharmaceuticals stock.

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as US$2.55 up to US$6.64. A popular way to gauge a stock's volatility is its "beta".

CPRX.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.5379. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Frequently asked questions

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site